MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN β-1b

Maria Pia Sormani; Paolo Bruzzi; K. Beckmann; Klaus Wagner; D. H. Miller; Ludwig Kappos; Massimo Filippi

doi:10.1212/01.wnl.0000063312.15758.b3

Abstract

1 min read

This study shows that the beneficial effect of IFNbeta-1b on disability accumulation in patients with secondary progressive MS is, to a large extent, independent of the changes detected using cMRI. As a consequence, cMRI metrics should not be used as a stand-alone measure of outcome in phase III trials of IFNbeta in secondary progressive MS.

Related publications

Article2001

Clinical–MRI correlations in a European trial of interferon beta-1b in secondary progressive MS

P. D. Molyneux, Gareth J. Barker, Frederik Barkhof, K. Beckmann, Frank Dahlke, Massimo Filippi, Mahdiyeh Khabbaz Koche Ghazi, David W. Hahn, Deirdre MacManus, Chris H. Polman, Carlo Pozzilli, Ludwig Kappos, Alan J. Thompson, Klaus Wagner, Tarek Yousry, D. H. Miller

Article2008

Magnetic resonance imaging metrics and their correlation with clinical outcomes in multiple sclerosis: a review of the literature and future perspectives

Dan Bar-Zohar, Federica Agosta, D. Goldstaub, Massimo Filippi

Article2002

MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN β-1b

Abstract

Discussion(0)

Related publications

Clinical–MRI correlations in a European trial of interferon beta-1b in secondary progressive MS

Magnetic resonance imaging metrics and their correlation with clinical outcomes in multiple sclerosis: a review of the literature and future perspectives

MRI metrics as surrogate markers for clinical relapse rate in relapsing-remitting MS patients

Magnetization Transfer MRI in Multiple Sclerosis

The effect of interferon β-1b on quantities derived from MT MRI in secondary progressive MS